0001209191-21-008662.txt : 20210208
0001209191-21-008662.hdr.sgml : 20210208
20210208211934
ACCESSION NUMBER: 0001209191-21-008662
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210205
FILED AS OF DATE: 20210208
DATE AS OF CHANGE: 20210208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHERMAN MARK ANDREW
CENTRAL INDEX KEY: 0001256708
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32431
FILM NUMBER: 21603575
MAIL ADDRESS:
STREET 1: DOLBY LABORATORIES, INC.
STREET 2: 1275 MARKET STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dolby Laboratories, Inc.
CENTRAL INDEX KEY: 0001308547
STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794]
IRS NUMBER: 900199783
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0927
BUSINESS ADDRESS:
STREET 1: 1275 MARKET STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
BUSINESS PHONE: 415 558 0200
MAIL ADDRESS:
STREET 1: 1275 MARKET STREET
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94103
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-05
0
0001308547
Dolby Laboratories, Inc.
DLB
0001256708
SHERMAN MARK ANDREW
C/O DOLBY LABORATORIES, INC.
1275 MARKET STREET
SAN FRANCISCO
CA
94103
0
1
0
0
EVP, GEN. COUN. & SECRTY
Class A Common Stock
2021-02-05
4
S
0
1436
91.6774
D
50237
D
Class A Common Stock
2021-02-05
4
S
0
227
92.23
D
50010
D
Class A Common Stock
2021-02-05
4
M
0
2882
45.50
A
52892
D
Class A Common Stock
2021-02-05
4
S
0
2707
91.4796
D
50185
D
Class A Common Stock
2021-02-05
4
S
0
175
92.23
D
50010
D
Class A Common Stock
2021-02-05
4
M
0
23118
45.50
A
73128
D
Class A Common Stock
2021-02-05
4
S
0
22622
91.5798
D
50506
D
Class A Common Stock
2021-02-05
4
S
0
496
92.23
D
50010
D
Employee Stock Option (right to buy)
45.50
2021-02-05
4
M
0
2882
0.00
D
2026-12-15
Class A Common Stock
2882
49118
D
Employee Stock Option (right to buy)
45.50
2021-02-05
4
M
0
23118
0.00
D
2023-12-15
Class A Common Stock
23118
0
D
The shares were sold in multiple transactions at prices ranging from $91.22 to $91.94, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Shares held following the reported transactions include 34,172 restricted stock units, which are subject to forfeiture until they vest
The shares were sold in multiple transactions at prices ranging from $91.17 to $92.08, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The shares were sold in multiple transactions at prices ranging from $91.135 to $92.08, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
This option was granted for a total of 52,000 shares of Class A Common Stock. 1/4 of the total number of shares issuable under the option vested on the first anniversary of December 15, 2016, the vesting commencement date, and the balance of the shares vested in equal monthly installments over the next 36 months thereafter.
This performance-based stock option award was granted for a total of 26,000 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 15, 2019 was at 95% of target, or 24,700 shares.
**All of the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.**
/s/ Daniel Rodriguez, Attorney-in-Fact for Andy Sherman
2021-02-08